Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 6/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4381665 | 0.86 | LMNA (0.51) | CD274SMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL4393726 | 0.83 | SMN1; SMN2 (0.41) | CD274SMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL4381735 | 0.81 | CD274 (0.40) | CD274SMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL4382486 | 0.77 | MTNR1A (0.34) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL4384303 | 0.76 | SMN1; SMN2 (0.39) | CD274SMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL4379079 | 0.76 | ALDH1A1 (0.36) | SMN1; SMN2ALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL4379012 | 0.75 | HDAC3 (0.34) | ALDH1A1 | |
| SCHEMBL4386867 | 0.75 | HTT (0.39) | SMN1; SMN2ALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL4387636 | 0.73 | ALDH1A1 (0.35) | SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL4386984 | 0.72 | CYP3A4 (0.35) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538241-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070155813-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-1704856-A1 | HSP90 FAMILY PROTEIN INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155813-A1 | Hsp90 family protein inhibitors | HSP90AB1, HEATR1, HSP90AB2P | CD274 2969/4885SMN1; SMN2 4471/4885ALDH1A1 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.